Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)
November 05, 2015 09:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced upcoming presentations related to KTE-C19, Kite's lead product candidate, that will take...
Kite Pharma to Present at Upcoming Investor Conferences in November 2015
November 04, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at several upcoming investor conferences this month:
Credit...
Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) to Support Registration of KTE-C19
November 02, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment
October 27, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif. and SEATTLE, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has entered into a worldwide research and license agreement with...
Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE
October 20, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications
October 15, 2015 08:00 ET
|
Kite Pharma, Inc.
COMP Opinions Recommend EU Orphan Designation for the Treatment of Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), and Follicular Lymphoma...
Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
October 07, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute...
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
October 01, 2015 05:01 ET
|
Kite Pharma, Inc.
- TCR product candidate targeting human papillomavirus (HPV)-16 E6 selectively kills cervical and head and neck cancer cells
- Phase 1/2 clinical trial of the HPV-16 E6 TCR is enrolling patients...
Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference
September 24, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the...
Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma's Board of Directors
September 15, 2015 03:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd.,...